| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/RHEUMATOLOGY/KEM089 |
| P698 | PubMed publication ID | 17449484 |
| P50 | author | Flavia Del Porto | Q56850401 |
| P2093 | author name string | Lai S | |
| Laganà B | |||
| Vitale M | |||
| D'Amelio R | |||
| Podestà E | |||
| Tinti F | |||
| Nofroni I | |||
| Mitterhofer AP | |||
| P433 | issue | 7 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 1111-1115 | |
| P577 | publication date | 2007-04-20 | |
| P1433 | published in | Rheumatology | Q7320492 |
| P1476 | title | Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis | |
| P478 | volume | 46 |
| Q36151574 | Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy |
| Q85069915 | Biologics and cardiovascular risk |
| Q24568196 | Biologics, cardiovascular effects and cancer |
| Q38260198 | Cardiovascular risk and the use of biologic agents in rheumatoid arthritis |
| Q34563216 | Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment |
| Q35557952 | Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing disease |
| Q41521795 | Disease duration of rheumatoid arthritis is a predictor of vascular stiffness: a cross-sectional study in patients without known cardiovascular comorbidities: A STROBE-compliant article |
| Q36113215 | Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy |
| Q36792775 | Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study |
| Q38976172 | Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis. |
| Q46075758 | Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis |
| Q51152425 | Inflammation-related cardiovascular morbidity : Pathophysiology and therapy |
| Q33686973 | Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis |
| Q37245192 | Infliximab improves vascular stiffness in patients with rheumatoid arthritis |
| Q35489690 | Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis |
| Q38104641 | Overview of vasculitis and vasculopathy in rheumatoid arthritis--something to think about |
| Q36943007 | Predictors of Atherosclerosis in Ankylosing Spondylitis |
| Q36245670 | Predictors of new atherosclerotic carotid plaque development in patients with rheumatoid arthritis: a longitudinal study |
| Q38612651 | Prevention of Stroke in Rheumatoid Arthritis |
| Q58728255 | Prospective assessment of cardiovascular risk parameters in patients with rheumatoid arthritis |
| Q38794852 | Rheumatoid Arthritis Pharmacotherapies: Do They Have Anti-Atherosclerotic Activity? |
| Q60592413 | Rheumatoid arthritis is sufficient to cause atheromatosis but not arterial stiffness or hypertrophy in the absence of classical cardiovascular risk factors |
| Q37472928 | Role for TNF in atherosclerosis? Lessons from autoimmune disease |
| Q36420808 | Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab |
| Q46458701 | Serum level of reactive oxygen metabolites (ROM) at 12 weeks of treatment with biologic agents for rheumatoid arthritis is a novel predictor for 52-week remission |
| Q38632110 | Stiff Substrates Increase Inflammation-Induced Endothelial Monolayer Tension and Permeability |
| Q34550743 | Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis |
| Q38519523 | Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis. |
| Q37206876 | The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus |
| Q37630351 | Vascular effects of biologic agents in RA and spondyloarthropathies |
| Q36993260 | Vascular involvement in rheumatic diseases: 'vascular rheumatology'. |
| Q28074148 | What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis? |
Search more.